



11-29-02

CASE 3-31105

RECEIVED
USPTO
NOV 29 2002
TECH CENTER 1600/2900
D 7571

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 195227376 US
Express Mail Label Number

November 26, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

MARTANI

Examiner: TRAN, S.

APPLICATION NO: 10/075,429

FILED: Feb. 13, 2002

FOR: RAPIDLY DISSOLVING DOSAGE FORM AND PROCESS FOR
MAKING SAME

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT - A

In the Specification:

Please replace the last paragraph beginning at line 23 of page 11 with the following rewritten paragraph:

B1
The disintegration agent can be any of those known in the art, e.g., croscarmellose Na; sodium glycolates of starch, e.g., Explotab® and Primojel®; cross-linked poly-N-vinyl-2-pyrrolidones, e.g., Polyplasdone® XL and Kollidon® CL; polymethylmethacrylates, e.g., Eudispert® HV; polysaccharides, e.g., Emcosoy®; or synthetic resins, e.g., Amberlite® IRP88. Preferred disintegration agents are croscarmellose Na, sodium starch glycolate (e.g., Primojel®) and cross-linked poly-N-vinyl-2-pyrrolidones (especially Polyplasdone® XL). The disintegration agent is typically present in an amount of at least 1, preferably of at least 5, and especially of at least 10 weight-% of the total dosage form, e.g. of from 1 up to 20 weight-%, especially of from 1 up to 15 weight-%.